Phosphate (Pi) is an essential mineral nutrient (Erem and Razzaque, 2018). Once absorbed and in circulation, Pi is utilized by cells for various structures and functions. Pi metabolism is regulated by a specific set of hormones to maintain physiological Pi concentrations. Fibroblast growth factor 23 (FGF23) is the chief hormone maintaining body Pi balance by promoting renal Pi excretion when Pi load is high (Fukumoto and Yamashita, 2007; Isakova et al., 2011). Dysregulation of this system causes either low (hypophosphatemia) or high (hyperphosphatemia) serum Pi levels (Farrow et al., 2011; White et al., 2001; Wolf, 2012). Hyperphosphatemic states can result from various conditions, including rare genetic disorders, such as familial tumoral calcinosis (FTC), and acquired diseases, such as chronic kidney disease (CKD), which are more frequent. Moreover, increased consumption of foods and drinks rich in Pi-based additives is expanding in Westernized diets, leading to excess dietary Pi intake (Carrigan et al., 2014; Gutiérrez et al., 2010a).

CKD patients have an increased risk of death that is attributable to complications such as inflammation, anemia, and skeletal muscle wasting (Amdur et al., 2016; Hoshino et al., 2020; Stenvinkel et al., 2016). The etiology of CKD-associated anemia is multifactorial and includes absolute iron deficiency and functional iron deficiency, with the latter caused by inflammatory cytokines including interleukin-6 (IL6) and interleukin-1β (IL1β). These inflammatory mediators can directly induce the release of the liver-hormone hepcidin, the master regulator of iron metabolism (Verga Falzacappa et al., 2007; Ganz and Nemeth, 2012; Kanamori et al., 2017). Hepcidin controls the flow of iron into circulation by regulating the iron exporter ferroportin (FPN) (Nemeth et al., 2004b). Hepcidin binding occludes FPN (Aschemeyer et al., 2018; Billesbølle et al., 2020) and induces its degradation, thereby restricting iron efflux into the circulation from iron recycling macrophages, a process also known as reticuloendothelial system (RES) blockade, and from duodenal enterocytes responsible for dietary iron absorption. Collectively, these events reduce serum iron levels (hypoferremia), limiting the supply of iron for erythrocyte production (Nemeth et al., 2004a).

Inflammatory cytokines such as IL6 and IL1β also act on skeletal muscle and induce muscle wasting, a comorbidity affecting 65% of CKD patients (Kovesdy et al., 2013; Li et al., 2009; Zhang et al., 2013). The loss of protein from muscle is ascribed to protein degradation by the ubiquitin–proteasome system, suppression of protein synthesis and impaired growth of new muscle fibers (Wang and Mitch, 2014). As pleotropic activities of IL6 and IL1β induce the production of myostatin, a pivotal mediator of skeletal muscle wasting, these actions foster the simultaneous induction of atrophy-related gene programs and reduced cellular responses to progrowth signals, which initiates protein synthesis suppression. Together, inflammation and myostatin advance these CKD-associated comorbidities which reduce the survival and quality of life of CKD patients (Zhang et al., 2011).

A prominent aspect of CKD is altered mineral metabolism, where hyperphosphatemia and excess serum FGF23 are factors associated with inflammation, anemia, and mortality (Mehta et al., 2017; Munoz Mendoza et al., 2017; Navarro-González et al., 2009; Tran et al., 2016). Drugs have been developed to control hyperphosphatemia, but reports show conflicting results about outcomes. Studies of the effects of dietary Pi restriction in animal models are scarce. Dietary interventions to lower Pi intake are challenging because they require long-term behavioral changes made more difficult by the lack of disclosure of Pi content of foods and beverages by the food industry (Gutiérrez and Wolf, 2010b).

All cell types rely on Pi for housekeeping roles, and metabolic Pi uptake is facilitated by three families of sodium–Pi (Na/Pi) cotransporters. Type III Na/Pi cotransporters, PiT-1 and PiT-2, are ubiquitously expressed and mediate cellular Pi homeostasis in all cells (Lederer and Miyamoto, 2012). Pathologic Pi accumulation in vasculature is mediated by PiT-1 and PiT-2, loading Pi into vascular smooth muscle cells where it activates signaling networks such as Ras/mitogen-activated protein kinase (MAPK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) (Chavkin et al., 2015; Turner et al., 2020; Zhao et al., 2011). These pathways provide plausible pathomechanisms that support excess Pi as a potential culprit behind the clinical association between hyperphosphatemia and CKD-associated vascular calcification.

Under physiologic conditions, bone-derived FGF23 targets the kidney to increase Pi excretion by activating its canonical signaling complex, fibroblast growth factor receptor 1 (FGFR1) and co-receptor Klotho (Czaya and Faul, 2019a). When FGF23 is in pathological excess, as found in dietary Pi overload or CKD, increased FGF23 targets the heart and liver by activating FGFR4, independently of Klotho (Faul et al., 2011; Grabner et al., 2015; Singh et al., 2016). This noncanonical mechanism recruits FGFR4 as a pathologic receptor mediating the effects of excess FGF23 to cause cardiac hypertrophy and promote inflammation (Faul et al., 2011; Grabner et al., 2015; Han et al., 2020; Leifheit-Nestler et al., 2017; Singh et al., 2016; Xiao et al., 2019). However, whether excess FGF23 and/or Pi directly contribute to functional iron deficiency or skeletal muscle wasting is unknown, and direct actions of excess Pi on the liver have not been studied to date.

In this study, we examine whether hyperphosphatemia and/or pathologic FGF23-FGFR4 signaling aggravates functional iron deficiency and skeletal muscle wasting, the common comorbidities in CKD. We expose mice constitutively lacking FGFR4 to hyperphosphatemia in the absence and presence of CKD. To further define the contribution of hyperphosphatemia, we subject Alport mice, a genetic model of progressive CKD, to a low Pi diet treatment. We identify a molecular mechanism in cultured mouse primary hepatocytes that links excess Pi to its actions on inflammation and iron metabolism, as increased inflammatory cytokines promote widespread pathologies and hepcidin production. Our findings reveal additional complications of hyperphosphatemia besides vascular calcification and identify plausible pathomechanisms underlying clinical associations between inflammation, anemia, and skeletal muscle wasting, which could be targeted therapeutically.

We report that hyperphosphatemia, either as a result of adenine-induced CKD or dietary Pi excess, increases inflammation to exacerbate anemia and skeletal muscle wasting (Figure 8). These complications are associated with increased liver Pi levels, which correlated with serum Pi concentrations. Supplying a low Pi diet treatment to Alport mice, a genetic model of CKD, results in beneficial outcomes that reduce functional iron deficiency and skeletal muscle wasting. Furthermore, our mechanistic in vitro studies indicate that Pi elevations induce hepatic production of IL6 and IL1β to increase hepcidin expression in hepatocytes, a potential causative link between hyperphosphatemia, anemia, and skeletal muscle dysfunction.

Figure 8

Download asset Open asset

Previously, we reported pathologic FGF23-FGFR4 signaling might contribute to excess inflammatory mediators (Singh et al., 2016), and we now followed up on the FGF23 inflammatory role in clinically relevant CKD models in vivo. Here, we examined wild-type (Fgfr4^+/+) and constitutive FGFR4 knockout (Fgfr4^−/−) mice subjected to adenine diet or a graded dietary Pi load. We found that on adenine, both Fgfr4^+/+ and Fgfr4^−/− mice show comparable macroscopic parameters (Table 1) and degrees of functional iron deficiency (Figure 1). These findings coincide with greater levels of liver Pi, which raises the possibility that pathologic Pi deposits, in tissues apart from the vasculature, may contribute to additional complications in CKD (Komaba and Fukagawa, 2016).

Clinical reports indicate CKD patients have dysregulated Pi handling (Chang et al., 2014; Isakova et al., 2009) and together with the consumption of foods and drinks rich in Pi-based additives, such as in a Westernized diet, extrarenal Pi accumulation may occur (Isakova et al., 2008). A recent study utilizing animal models supports this postulate, demonstrating that excess Pi leads to depositions into tissues such as the vasculature (Zelt et al., 2019). Moreover, a recent report indicates the major source of body Pi removed during hemodialysis in CKD patients, is from cells releasing intracellular Pi (Chazot et al., 2021). As the serum Pi compartment represents a small fraction of total body Pi, and the uptake of excess Pi by tissues is recognized as a detrimental trigger, it is important to examine the degree of pathologic Pi accumulation in nonvascular tissue and whether it exacerbates complications in CKD, such as anemia and muscle wasting.

We employed a graded Pi diet to study the effects of excess Pi on the liver (Figure 2). Studies show conflicting results toward renal and liver health, following supplementation of a high Pi diet (Baquerizo et al., 2003; Haut et al., 1980; Ugrica et al., 2021). In our study, no significant changes in macroscopic parameters were observed following dietary Pi overload (Table 2). Also, no pathologic changes in kidney (Figure 2—figure supplement 1) or liver were detected (Figure 2—figure supplement 2). However, mice on a 3% Pi diet exhibit increased liver inflammation and Hamp expression, which corroborates previous observation that high dietary Pi influences hepcidin production (Nakao et al., 2015). These results coincide with positive correlations between liver Pi and liver Hamp mRNA expression, with onset of this correlation preceding significant elevations in serum Pi. Despite these data suggesting that liver Pi influences liver hepcidin production, our finding might indicate that increased extrarenal Pi accumulation provides a reservoir for storing excess Pi until tissue accumulation achieves saturation, in which case the serum Pi compartment then gradually rises, resulting in hyperphosphatemia. Furthermore, our data suggest that prolonged exposure to Pi, if not maintained in adequate quantities, might trigger pathologic outcomes, as mice on 3% Pi show a noticeable degree of hypoferremia. None of the observed effects of the high Pi diet were mediated by FGFR4, as Fgfr4^−/− mice were comparable to wild-type mice in all the parameters measured. However, this work cannot exclude the potential of alternative FGFR isoforms which might mediate the effects of excess FGF23 toward functional iron deficiency following either adenine or 3% Pi diet, as a previous report exhibits the utilization of a single intraperitoneal injection of FGF23 blocking peptide was sufficient to rescue anemia (Agoro et al., 2018).

Excess dietary Pi was shown to directly exacerbate intestinal inflammation in a model of experimental colitis (Sugihara et al., 2017) and that reducing dietary Pi provides beneficial outcomes toward systemic inflammation, accelerated aging, and survival, as demonstrated in a model of senescence (Morishita et al., 2001). We likewise observed increased inflammation in our hyperphosphatemic mouse models. Inflammatory cytokines can directly target skeletal muscle cells to induce muscle wasting by increasing myostatin production (Zhang et al., 2013), which both together, enhances protein degradation and reduces protein synthesis, as CKD illustrates catabolic conditions which are attributable to the vicious cycle generated between mineral dyshomeostasis and inflammation (Czaya and Faul, 2019b). We indeed observed skeletal muscle wasting in adenine-induced CKD, high phosphate diet, and genetic model of CKD. Ablation of FGFR4 in mice did not improve skeletal muscle function following adenine or 3% Pi diets, suggesting hyperphosphatemia rather than pathologic FGF23-FGFR4 signaling might be the cause of skeletal muscle abnormalities (Figure 3). This hypothesis is supported by reports demonstrating excess Pi influences skeletal muscle dysfunction (Acevedo et al., 2016; Chen et al., 2018; Chung et al., 2020), although it is possible additional FGFR isoforms directly promote skeletal muscle wasting due to excess FGF23 following adenine or high Pi diet. However, a recent report suggests that FGF23 does not directly affect skeletal muscle dysfunction (Avin et al., 2018).

To assess whether reducing hyperphosphatemia can improve inflammation, anemia, and skeletal muscle wasting, we exposed Alport mice, a genetic model of progressive CKD, to a low Pi diet treatment. Indeed, despite severe elevations in serum FGF23, dietary Pi restriction limited functional iron deficiency (Figure 4). Our data also show liver Pi levels were reduced in Alport mice following low Pi diet treatment, in comparison to Alport mice on normal diet. These findings provide strong evidence that hyperphosphatemia, specifically pathologic liver Pi accumulation, rather than pathologic FGF23-FGFR4 signaling, might exacerbate inflammation and hypoferremia. Skeletal muscle function and mass were also improved by a low Pi diet in Alport mice, along with decreased expression of muscle myostatin and atrophy-related gene programs, culminating in larger myofiber size. These findings suggest the contribution of hyperphosphatemia to skeletal muscle wasting may result from an indirect mechanism that regulates inflammatory cytokines and their pleotropic activities, such as increased liver-derived IL1β and IL6, which might increase overall systemic levels that effectively target skeletal muscle. Despite this postulate, further work will be needed to determine if high extracellular Pi directly targets skeletal muscle cells to affect muscle function. Nonetheless, these data add to the growing list of adverse outcomes of Pi toxicity such as gingivitis, accelerated aging, vascular calcification and tumorigenesis (Erem and Razzaque, 2018). Furthermore, Alport mice on low Pi diet treatment displayed a reduced degree of pathologic kidney function, alterations in kidney morphology, and macroscopic parameters (Figure 4, Figure 4—figure supplement 1, Table 3). Thus, we cannot exclude that these beneficial outcomes in Alport mice observed on treatment may be a repercussion of slightly improved kidney function, as a recent report demonstrates elevated Pi concentrations directly affect proximal tubular function (Shiizaki et al., 2021).

Importantly, we identify a molecular mechanism that potentially links hyperphosphatemia to anemia and skeletal muscle dysfunction. Utilizing mouse primary hepatocytes, we demonstrate high extracellular Pi activates NFκB signaling and leads to subsequent inflammatory cytokine and hepcidin production (Figure 6). Employing PFA, a compound reported to reduce calcium–Pi deposition and cluster formation, as aggregates are a byproduct of increased extracellular Pi (Villa-Bellosta et al., 2007; Villa-Bellosta and Sorribas, 2009), we confirm NFκB activation is a direct action of Pi targeting hepatocytes, which prompts subsequent Slc20a1 mRNA expression, as observed from our BAY 11-7082 findings. This high extracellular Pi-NFκB signaling axis is observed in other reservoirs such as vascular smooth muscle cells and ex vivo kidney slices, as well as adjuncts the rewiring of various signaling networks that control cellular homeostasis following excessive Pi exposure (He et al., 2021; Rodríguez-Ortiz et al., 2020; Voelkl et al., 2018; Zhao et al., 2011). Although this reaffirms NFκB directly influences PiT-1 levels (Koumakis et al., 2019), it does not identify if our observations are dependent or independent of Pi translocation, as extracellular Pi might associate with various PiT-1 extracellular regions to influence PiT-1/PiT-1 homodimerization, PiT-1/PiT-2 heterodimerization or a conformational change in PiT-1 to initiate the activation of selected binding partners which mediate downstream signaling events (Bon et al., 2018; Forand et al., 2016). In addition to the amplified hepatic PiT-1 abundance and recognition of NFκB as a necessary mediator of high extracellular Pi in hepatocytes, we show that the effect of Pi on hepcidin requires the indirect actions of NFκB and biological activities of endogenous IL1β and IL6 proteins secreted by hepatocytes, as elucidated by our cell-based neutralization assay of these targeted cytokines (Figure 7). Based on these findings, we speculate increased liver Pi deposits might underlie a clinical association between elevated body Pi and inflammation, where the prolonged duration of tissue accumulation permits Pi in the liver to directly target hepatocytes to induce inflammatory gene programs and hepcidin expression, contributing to hypoferremia. This could explain associations of inflammation and anemia in FTC patients, in addition to patients with and without CKD, before they exhibit hyperphosphatemia (Ramnitz et al., 2016; Tran et al., 2016; Wojcicki, 2013).

Our study has some limitations. Although we confirm hyperphosphatemia affects specific complications, our study does not specifically address the actions of certain aggregate byproducts formed by increased extracellular Pi. Nonetheless, this principal emphasis on elevations in plasma Pi concentrations will ultimately impact the formation of byproducts. Notably, the identification of the specific Pi sensor which mediates our observed hepatic Pi actions are not definite and remains to be defined with our ongoing studies. Moreover, our study does not address the specific actions of hyperphosphatemia on bone metabolism. As bone is a reservoir of extracellular Pi, potential alterations in bone health could relay a crosstalk between bone, liver, and/or skeletal muscle, which might contribute to our reported observations.

In summary, we investigated whether hyperphosphatemia and/or pathologic FGF23-FGFR4 signaling aggravates inflammation, anemia, and skeletal muscle wasting. We establish hyperphosphatemia, as found in dietary Pi overload or in CKD, is a detrimental trigger which activates hepatic NFκB signaling to stimulate an inflammatory response, which in turn, exacerbates hypoferremia and widespread complications such as skeletal muscle wasting. Notably, these findings are independent of pathologic FGF23-FGFR4 signaling. Clinical studies have demonstrated conflicting outcomes with traditional Pi binders in individuals with nondialysis-dependent CKD, but modern Pi binders, such as ferric citrate, demonstrate greater efficacy (Francis et al., 2019; Toussaint et al., 2020), and are being evaluated for their effect on CKD comorbidities. Furthermore, reports assessing dietary Pi restriction in animal models are scarce. Our current experimental data suggest hyperphosphatemia, in itself, is pathologic and demands further attention for alternative strategies to resolve current ineffective approaches. Treatments, such as pharmacologic inhibition of type II Na/Pi cotransporters, hold potential for therapeutic actions (Clerin et al., 2020; Thomas et al., 2019) but do not aim at altered mineral metabolism. Using in vitro studies and complementary animal models, we provide insights regarding the interconnection between altered mineral metabolism and common complications. Dietary Pi restriction might alleviate these sequelae, if sustained effectively as a clinical treatment. By elucidating direct inflammatory actions of high extracellular Pi on hepatocytes, we expose additional adverse outcomes of hyperphosphatemia, besides vascular calcification. These findings may yield new targets for therapeutic development, with emphasis on hepatic Pi actions. Moreover, as studies indicate anti-FGFR4 therapy may be beneficial toward cardiomyopathy (Grabner et al., 2015), our data suggest these same beneficial outcomes for inflammation, anemia, and skeletal muscle wasting would not apply. Altogether, our study features a possibility to improve CKD patient survival and specific rare genetic disorders, such as FTC, by limiting excess body Pi.

All data generated and analyzed during this study are available through Dryad.

1. 1. Faul C

   (2022) Dryad Digital Repository

   Data from: Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling full source data.

   https://doi.org/10.5061/dryad.6t1g1jx0f

1. 1. Acevedo LM
   2. López I
   3. Peralta-Ramírez A
   4. Pineda C
   5. Chamizo VE
   6. Rodríguez M
   7. Aguilera-Tejero E
   8. Rivero JLL

   (2016) High-phosphorus diet maximizes and low-dose calcitriol attenuates skeletal muscle changes in long-term uremic rats

   Journal of Applied Physiology (Bethesda, Md) 120:1059–1069.

   https://doi.org/10.1152/japplphysiol.00957.2015

   • PubMed
   • Google Scholar
2. 1. Agoro R
   2. Montagna A
   3. Goetz R
   4. Aligbe O
   5. Singh G
   6. Coe LM
   7. Mohammadi M
   8. Rivella S
   9. Sitara D

   (2018) Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia

   FASEB Journal 32:3752–3764.

   https://doi.org/10.1096/fj.201700667R

   • PubMed
   • Google Scholar
3. 1. Amdur RL
   2. Feldman HI
   3. Gupta J
   4. Yang W
   5. Kanetsky P
   6. Shlipak M
   7. Rahman M
   8. Lash JP
   9. Townsend RR
   10. Ojo A
   11. Roy-Chaudhury A
   12. Go AS
   13. Joffe M
   14. He J
   15. Balakrishnan VS
   16. Kimmel PL
   17. Kusek JW
   18. Raj DS

   (2016) Inflammation and Progression of CKD: The CRIC Study

   Clin J Am Soc Nephro 11:1546–1556.

   https://doi.org/10.2215/cjn.13121215

   • Google Scholar
4. 1. Aschemeyer S
   2. Qiao B
   3. Stefanova D
   4. Valore EV
   5. Sek AC
   6. Ruwe TA
   7. Vieth KR
   8. Jung G
   9. Casu C
   10. Rivella S
   11. Jormakka M
   12. Mackenzie B
   13. Ganz T
   14. Nemeth E

   (2018) Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin

   Blood 131:899–910.

   https://doi.org/10.1182/blood-2017-05-786590

   • PubMed
   • Google Scholar
5. 1. Avin KG
   2. Vallejo JA
   3. Chen NX
   4. Wang K
   5. Touchberry CD
   6. Brotto M
   7. Dallas SL
   8. Moe SM
   9. Wacker MJ

   (2018) Fibroblast growth factor 23 does not directly influence skeletal muscle cell proliferation and differentiation or ex vivo muscle contractility

   American Journal of Physiology. Endocrinology and Metabolism 315:E594–E604.

   https://doi.org/10.1152/ajpendo.00343.2017

   • PubMed
   • Google Scholar
6. 1. Baquerizo A
   2. Anselmo D
   3. Shackleton C
   4. Chen TW
   5. Cao C
   6. Weaver M
   7. Gornbein J
   8. Geevarghese S
   9. Nissen N
   10. Farmer D
   11. Demetriou A
   12. Busuttil RW

   (2003) Phosphorus ans an early predictive factor in patients with acute liver failure1

   Transplantation 75:2007–2014.

   https://doi.org/10.1097/01.TP.0000063219.21313.32

   • PubMed
   • Google Scholar
7. 1. Billesbølle CB
   2. Azumaya CM
   3. Kretsch RC
   4. Powers AS
   5. Gonen S
   6. Schneider S
   7. Arvedson T
   8. Dror RO
   9. Cheng Y
   10. Manglik A

   (2020) Structure of hepcidin-bound ferroportin reveals iron homeostatic mechanisms

   Nature 586:807–811.

   https://doi.org/10.1038/s41586-020-2668-z

   • PubMed
   • Google Scholar
8. 1. Bon N
   2. Couasnay G
   3. Bourgine A
   4. Sourice S
   5. Beck-Cormier S
   6. Guicheux J
   7. Beck L

   (2018) Phosphate (Pi)-regulated heterodimerization of the high-affinity sodium-dependent Pi transporters PiT1/Slc20a1 and PiT2/Slc20a2 underlies extracellular Pi sensing independently of Pi uptake

   Journal of Biological Chemistry 293:2102–2114.

   https://doi.org/10.1074/jbc.M117.807339

   • PubMed
   • Google Scholar
9. 1. Carrigan A
   2. Klinger A
   3. Choquette SS
   4. Luzuriaga-McPherson A
   5. Bell EK
   6. Darnell B
   7. Gutiérrez OM

   (2014) Contribution of Food Additives to Sodium and Phosphorus Content of Diets Rich in Processed Foods

   Journal of Renal Nutrition 24:13–19.

   https://doi.org/10.1053/j.jrn.2013.09.003

   • PubMed
   • Google Scholar
10. 1. Chang AR
    2. Lazo M
    3. Appel LJ
    4. Gutiérrez OM
    5. Grams ME

    (2014) High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III

    The American Journal of Clinical Nutrition 99:320–327.

    https://doi.org/10.3945/ajcn.113.073148

    • PubMed
    • Google Scholar
11. 1. Chavkin NW
    2. Chia JJ
    3. Crouthamel MH
    4. Giachelli CM

    (2015) Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells

    Experimental Cell Research 333:39–48.

    https://doi.org/10.1016/j.yexcr.2015.02.002

    • PubMed
    • Google Scholar
12. 1. Chazot G
    2. Lemoine S
    3. Kocevar G
    4. Kalbacher E
    5. Sappey-Marinier D
    6. Rouvière O
    7. Juillard L

    (2021) Intracellular Phosphate and ATP Depletion Measured by Magnetic Resonance Spectroscopy in Patients Receiving Maintenance Hemodialysis

    Journal of the American Society of Nephrology 32:229–237.

    https://doi.org/10.1681/ASN.2020050716

    • PubMed
    • Google Scholar
13. 1. Chen YY
    2. Kao TW
    3. Chou CW
    4. Wu CJ
    5. Yang HF
    6. Lai CH
    7. Wu LW
    8. Chen WL

    (2018) Exploring the Link between Serum Phosphate Levels and Low Muscle Strength, Dynapenia, and Sarcopenia

    Scientific Reports 8:3573.

    https://doi.org/10.1038/s41598-018-21784-1

    • PubMed
    • Google Scholar
14. 1. Chung LH
    2. Liu ST
    3. Huang SM
    4. Salter DM
    5. Lee HS
    6. Hsu YJ

    (2020) High phosphate induces skeletal muscle atrophy and suppresses myogenic differentiation by increasing oxidative stress and activating Nrf2 signaling

    Aging 12:21446–21468.

    https://doi.org/10.18632/aging.103896

    • PubMed
    • Google Scholar
15. 1. Clerin V
    2. Saito H
    3. Filipski KJ
    4. Nguyen AH
    5. Garren J
    6. Kisucka J
    7. Reyes M
    8. Jüppner H

    (2020) Selective pharmacological inhibition of the sodium-dependent phosphate co-transporter NPT2a promotes phosphate excretion

    The Journal of Clinical Investigation 130:6510–6522.

    https://doi.org/10.1172/JCI135665

    • PubMed
    • Google Scholar
16. 1. Cosgrove D
    2. Meehan DT
    3. Grunkemeyer JA
    4. Kornak JM
    5. Sayers R
    6. Hunter WJ
    7. Samuelson GC

    (1996) Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome

    Genes & Development 10:2981–2992.

    https://doi.org/10.1101/gad.10.23.2981

    • PubMed
    • Google Scholar
17. 1. Czaya B
    2. Faul C

    (2019a) FGF23 and inflammation—a vicious coalition in CKD

    Kidney International 96:813–815.

    https://doi.org/10.1016/j.kint.2019.05.018

    • PubMed
    • Google Scholar
18. 1. Czaya B
    2. Faul C

    (2019b) The Role of Fibroblast Growth Factor 23 in Inflammation and Anemia

    International Journal of Molecular Sciences 20:4195.

    https://doi.org/10.3390/ijms20174195

    • PubMed
    • Google Scholar
19. 1. Erem S
    2. Razzaque MS

    (2018) Dietary phosphate toxicity: an emerging global health concern

    Histochemistry and Cell Biology 150:711–719.

    https://doi.org/10.1007/s00418-018-1711-8

    • PubMed
    • Google Scholar
20. 1. Farrow EG
    2. Imel EA
    3. White KE

    (2011) Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho)

    Best Practice & Research Clinical Rheumatology 25:735–747.

    https://doi.org/10.1016/j.berh.2011.10.020

    • Google Scholar
21. 1. Faul C
    2. Amaral AP
    3. Oskouei B
    4. Hu M-C
    5. Sloan A
    6. Isakova T
    7. Gutiérrez OM
    8. Aguillon-Prada R
    9. Lincoln J
    10. Hare JM
    11. Mundel P
    12. Morales A
    13. Scialla J
    14. Fischer M
    15. Soliman EZ
    16. Chen J
    17. Go AS
    18. Rosas SE
    19. Nessel L
    20. Townsend RR
    21. Feldman HI
    22. St John Sutton M
    23. Ojo A
    24. Gadegbeku C
    25. Di Marco GS
    26. Reuter S
    27. Kentrup D
    28. Tiemann K
    29. Brand M
    30. Hill JA
    31. Moe OW
    32. Kuro-O M
    33. Kusek JW
    34. Keane MG
    35. Wolf M

    (2011) FGF23 induces left ventricular hypertrophy

    The Journal of Clinical Investigation 121:4393–4408.

    https://doi.org/10.1172/JCI46122

    • PubMed
    • Google Scholar
22. 1. Forand A
    2. Koumakis E
    3. Rousseau A
    4. Sassier Y
    5. Journe C
    6. Merlin JF
    7. Leroy C
    8. Boitez V
    9. Codogno P
    10. Friedlander G
    11. Cohen I

    (2016) Disruption of the Phosphate Transporter Pit1 in Hepatocytes Improves Glucose Metabolism and Insulin Signaling by Modulating the USP7/IRS1 Interaction

    Cell Reports 16:2736–2748.

    https://doi.org/10.1016/j.celrep.2016.08.012

    • PubMed
    • Google Scholar
23. 1. Francis C
    2. Courbon G
    3. Gerber C
    4. Neuburg S
    5. Wang X
    6. Dussold C
    7. Capella M
    8. Qi L
    9. Isakova T
    10. Mehta R
    11. Martin A
    12. Wolf M
    13. David V

    (2019) Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease

    Kidney International 96:1346–1358.

    https://doi.org/10.1016/j.kint.2019.07.026

    • PubMed
    • Google Scholar
24. 1. Fukumoto S
    2. Yamashita T

    (2007) FGF23 is a hormone-regulating phosphate metabolism—Unique biological characteristics of FGF23

    Bone 40:1190–1195.

    https://doi.org/10.1016/j.bone.2006.12.062

    • PubMed
    • Google Scholar
25. 1. Ganz T
    2. Nemeth E

    (2012) Hepcidin and iron homeostasis

    Biochimica et Biophysica Acta 1823:1434–1443.

    https://doi.org/10.1016/j.bbamcr.2012.01.014

    • PubMed
    • Google Scholar
26. 1. Grabner A
    2. Amaral AP
    3. Schramm K
    4. Singh S
    5. Sloan A
    6. Yanucil C
    7. Li J
    8. Shehadeh LA
    9. Hare JM
    10. David V
    11. Martin A
    12. Fornoni A
    13. Di Marco GS
    14. Kentrup D
    15. Reuter S
    16. Mayer AB
    17. Pavenstädt H
    18. Stypmann J
    19. Kuhn C
    20. Hille S
    21. Frey N
    22. Leifheit-Nestler M
    23. Richter B
    24. Haffner D
    25. Abraham R
    26. Bange J
    27. Sperl B
    28. Ullrich A
    29. Brand M
    30. Wolf M
    31. Faul C

    (2015) Activation of Cardiac Fibroblast Growth Factor Receptor 4 Causes Left Ventricular Hypertrophy

    Cell Metabolism 22:1020–1032.

    https://doi.org/10.1016/j.cmet.2015.09.002

    • PubMed
    • Google Scholar
27. 1. Gutiérrez OM
    2. Anderson C
    3. Isakova T
    4. Scialla J
    5. Negrea L
    6. Anderson AH
    7. Bellovich K
    8. Chen J
    9. Robinson N
    10. Ojo A
    11. Lash J
    12. Feldman HI
    13. Wolf M
    14. CRIC Study Group

    (2010a) Low Socioeconomic Status Associates with Higher Serum Phosphate Irrespective of Race

    Journal of the American Society of Nephrology 21:1953–1960.

    https://doi.org/10.1681/ASN.2010020221

    • PubMed
    • Google Scholar
28. 1. Gutiérrez OM
    2. Wolf M

    (2010b) Dietary Phosphorus Restriction in Advanced Chronic Kidney Disease: Merits, Challenges, and Emerging Strategies

    Seminars in Dialysis 23:401–406.

    https://doi.org/10.1111/j.1525-139X.2010.00750.x

    • PubMed
    • Google Scholar
29. 1. Han X
    2. Cai C
    3. Xiao Z
    4. Quarles LD

    (2020) FGF23 induced left ventricular hypertrophy mediated by FGFR4 signaling in the myocardium is attenuated by soluble Klotho in mice

    Journal of Molecular and Cellular Cardiology 138:66–74.

    https://doi.org/10.1016/j.yjmcc.2019.11.149

    • PubMed
    • Google Scholar
30. 1. Haut LL
    2. Alfrey AC
    3. Guggenheim S
    4. Buddington B
    5. Schrier N

    (1980) Renal toxicity of phosphate in rats

    Kidney International 17:722–731.

    https://doi.org/10.1038/ki.1980.85

    • PubMed
    • Google Scholar
31. 1. He P
    2. Mann-Collura O
    3. Fling J
    4. Edara N
    5. Hetz R
    6. Razzaque MS

    (2021) High phosphate actively induces cytotoxicity by rewiring pro‐survival and pro‐apoptotic signaling networks in HEK293 and HeLa cells

    FASEB Journal 35:e20997.

    https://doi.org/10.1096/fj.202000799RR

    • PubMed
    • Google Scholar
32. 1. Hoshino J
    2. Muenz D
    3. Zee J
    4. Sukul N
    5. Speyer E
    6. Guedes M
    7. Lopes AA
    8. Asahi K
    9. van Haalen H
    10. James G
    11. Dhalwani N
    12. Pecoits-Filho R
    13. Bieber B
    14. Robinson BM
    15. Pisoni RL
    16. CKDopps Investigators

    (2020) Associations of Hemoglobin Levels With Health-Related Quality of Life, Physical Activity, and Clinical Outcomes in Persons With Stage 3-5 Nondialysis CKD

    Journal of Renal Nutrition 30:404–414.

    https://doi.org/10.1053/j.jrn.2019.11.003

    • PubMed
    • Google Scholar
33. 1. Isakova T
    2. Gutierrez O
    3. Shah A
    4. Castaldo L
    5. Holmes J
    6. Lee H
    7. Wolf M

    (2008) Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKD

    Journal of the American Society of Nephrology 19:615–623.

    https://doi.org/10.1681/ASN.2007060673

    • PubMed
    • Google Scholar
34. 1. Isakova T
    2. Gutiérrez OM
    3. Chang Y
    4. Shah A
    5. Tamez H
    6. Smith K
    7. Thadhani R
    8. Wolf M

    (2009) Phosphorus Binders and Survival on Hemodialysis

    Journal of the American Society of Nephrology 20:388–396.

    https://doi.org/10.1681/ASN.2008060609

    • PubMed
    • Google Scholar
35. 1. Isakova T
    2. Wahl P
    3. Vargas GS
    4. Gutiérrez OM
    5. Scialla J
    6. Xie H
    7. Appleby D
    8. Nessel L
    9. Bellovich K
    10. Chen J
    11. Hamm L
    12. Gadegbeku C
    13. Horwitz E
    14. Townsend RR
    15. Anderson CAM
    16. Lash JP
    17. Hsu C-Y
    18. Leonard MB
    19. Wolf M

    (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease

    Kidney International 79:1370–1378.

    https://doi.org/10.1038/ki.2011.47

    • PubMed
    • Google Scholar
36. 1. Kanamori Y
    2. Murakami M
    3. Sugiyama M
    4. Hashimoto O
    5. Matsui T
    6. Funaba M

    (2017) Interleukin-1β (IL-1β) transcriptionally activates hepcidin by inducing CCAAT enhancer-binding protein δ (C/EBPδ) expression in hepatocytes

    The Journal of Biological Chemistry 292:10275–10287.

    https://doi.org/10.1074/jbc.M116.770974

    • PubMed
    • Google Scholar
37. 1. Komaba H
    2. Fukagawa M

    (2016) Phosphate—a poison for humans?

    Kidney International 90:753–763.

    https://doi.org/10.1016/j.kint.2016.03.039

    • PubMed
    • Google Scholar
38. 1. Koumakis E
    2. Millet-Botti J
    3. Benna JE
    4. Leroy C
    5. Boitez V
    6. Codogno P
    7. Friedlander G
    8. Forand A

    (2019) Novel function of PiT1/SLC20A1 in LPS-related inflammation and wound healing

    Scientific Reports 9:1808.

    https://doi.org/10.1038/s41598-018-37551-1

    • PubMed
    • Google Scholar
39. 1. Kovesdy CP
    2. Kopple JD
    3. Kalantar-Zadeh K

    (2013) Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: reconciling low protein intake with nutritional therapy

    The American Journal of Clinical Nutrition 97:1163–1177.

    https://doi.org/10.3945/ajcn.112.036418

    • PubMed
    • Google Scholar
40. 1. Lederer E
    2. Miyamoto K

    (2012) Clinical Consequences of Mutations in Sodium Phosphate Cotransporters

    Clinical Journal of the American Society of Nephrology 7:1179–1187.

    https://doi.org/10.2215/CJN.09090911

    • PubMed
    • Google Scholar
41. 1. Leifheit-Nestler M
    2. Grabner A
    3. Hermann L
    4. Richter B
    5. Schmitz K
    6. Fischer DC
    7. Yanucil C
    8. Faul C
    9. Haffner D

    (2017) Vitamin D treatment attenuates cardiac FGF23/FGFR4 signaling and hypertrophy in uremic rats

    Nephrology, Dialysis, Transplantation 32:1493–1503.

    https://doi.org/10.1093/ndt/gfw454

    • PubMed
    • Google Scholar
42. 1. Li W
    2. Moylan JS
    3. Chambers MA
    4. Smith J
    5. Reid MB

    (2009) Interleukin-1 stimulates catabolism in C2C12 myotubes

    Am J Physiol-Cell Ph 297:C706–C714.

    https://doi.org/10.1152/ajpcell.00626.2008

    • Google Scholar
43. 1. Mehta R
    2. Cai X
    3. Hodakowski A
    4. Lee J
    5. Leonard M
    6. Ricardo A
    7. Chen J
    8. Hamm L
    9. Sondheimer J
    10. Dobre M
    11. David V
    12. Yang W
    13. Go A
    14. Kusek JW
    15. Feldman H
    16. Wolf M
    17. Isakova T
    18. Investigators CS

    (2017) Fibroblast Growth Factor 23 and Anemia in the Chronic Renal Insufficiency Cohort Study

    Clinical Journal of the American Society of Nephrology 12:1795–1803.

    https://doi.org/10.2215/CJN.03950417

    • PubMed
    • Google Scholar
44. 1. Morishita K
    2. Shirai A
    3. Kubota M
    4. Katakura Y
    5. Nabeshima Y
    6. Takeshige K
    7. Kamiya T

    (2001) The Progression of Aging in Klotho Mutant Mice Can Be Modified by Dietary Phosphorus and Zinc

    The Journal of Nutrition 131:3182–3188.

    https://doi.org/10.1093/jn/131.12.3182

    • PubMed
    • Google Scholar
45. 1. Munoz Mendoza J
    2. Isakova T
    3. Cai X
    4. Bayes LY
    5. Faul C
    6. Scialla JJ
    7. Lash JP
    8. Chen J
    9. He J
    10. Navaneethan S
    11. Negrea L
    12. Rosas SE
    13. Kretzler M
    14. Nessel L
    15. Xie D
    16. Anderson AH
    17. Raj DS
    18. Wolf M
    19. CRIC Study Investigators

    (2017) Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease

    Kidney International 91:711–719.

    https://doi.org/10.1016/j.kint.2016.10.021

    • PubMed
    • Google Scholar
46. 1. Nakao M
    2. Yamamoto H
    3. Nakahashi O
    4. Ikeda S
    5. Abe K
    6. Masuda M
    7. Ishiguro M
    8. Iwano M
    9. Takeda E
    10. Taketani Y

    (2015) Dietary phosphate supplementation delays the onset of iron deficiency anemia and affects iron status in rats

    Nutrition Research (New York, N.Y.) 35:1016–1024.

    https://doi.org/10.1016/j.nutres.2015.09.001

    • PubMed
    • Google Scholar
47. 1. Navarro-González JF
    2. Mora-Fernández C
    3. Muros M
    4. Herrera H
    5. García J

    (2009) Mineral Metabolism and Inflammation in Chronic Kidney Disease Patients: A Cross-Sectional Study

    Clinical Journal of the American Society of Nephrology 4:1646–1654.

    https://doi.org/10.2215/CJN.02420409

    • PubMed
    • Google Scholar
48. 1. Nemeth E
    2. Rivera S
    3. Gabayan V
    4. Keller C
    5. Taudorf S
    6. Pedersen BK
    7. Ganz T

    (2004a) IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

    The Journal of Clinical Investigation 113:1271–1276.

    https://doi.org/10.1172/JCI20945

    • PubMed
    • Google Scholar
49. 1. Nemeth E
    2. Tuttle MS
    3. Powelson J
    4. Vaughn MB
    5. Donovan A
    6. Ward DM
    7. Ganz T
    8. Kaplan J

    (2004b) Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization

    Science (New York, N.Y.) 306:2090–2093.

    https://doi.org/10.1126/science.1104742

    • PubMed
    • Google Scholar
50. 1. Noonan ML
    2. Clinkenbeard EL
    3. Ni P
    4. Swallow EA
    5. Tippen SP
    6. Agoro R
    7. Allen MR
    8. White KE

    (2020) Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)

    Physiological Reports 8:e14434.

    https://doi.org/10.14814/phy2.14434

    • PubMed
    • Google Scholar
51. 1. Pierce JW
    2. Schoenleber R
    3. Jesmok G
    4. Best J
    5. Moore SA
    6. Collins T
    7. Gerritsen ME

    (1997) Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo

    The Journal of Biological Chemistry 272:21096–21103.

    https://doi.org/10.1074/jbc.272.34.21096

    • Google Scholar
52. 1. Raj DSC
    2. Moseley P
    3. Dominic EA
    4. Onime A
    5. Tzamaloukas AH
    6. Boyd A
    7. Shah VO
    8. Glew R
    9. Wolfe R
    10. Ferrando A

    (2008) Interleukin-6 modulates hepatic and muscle protein synthesis during hemodialysis

    Kidney International 73:1054–1061.

    https://doi.org/10.1038/ki.2008.21

    • PubMed
    • Google Scholar
53. 1. Ramnitz MS
    2. Gourh P
    3. Goldbach-Mansky R
    4. Wodajo F
    5. Ichikawa S
    6. Econs MJ
    7. White KE
    8. Molinolo A
    9. Chen MY
    10. Heller T
    11. Del Rivero J
    12. Seo-Mayer P
    13. Arabshahi B
    14. Jackson MB
    15. Hatab S
    16. McCarthy E
    17. Guthrie LC
    18. Brillante BA
    19. Gafni RI
    20. Collins MT

    (2016) Phenotypic and Genotypic Characterization and Treatment of a Cohort With Familial Tumoral Calcinosis/Hyperostosis‐Hyperphosphatemia Syndrome

    Journal of Bone and Mineral Research 31:1845–1854.

    https://doi.org/10.1002/jbmr.2870

    • PubMed
    • Google Scholar
54. 1. Rodríguez-Ortiz ME
    2. Díaz-Tocados JM
    3. Muñoz-Castañeda JR
    4. Herencia C
    5. Pineda C
    6. Martínez-Moreno JM
    7. Montes de Oca A
    8. López-Baltanás R
    9. Alcalá-Díaz J
    10. Ortiz A
    11. Aguilera-Tejero E
    12. Felsenfeld A
    13. Rodríguez M
    14. Almadén Y

    (2020) Inflammation both increases and causes resistance to FGF23 in normal and uremic rats

    Clinical Science (London, England) 134:15–32.

    https://doi.org/10.1042/CS20190779

    • PubMed
    • Google Scholar
55. 1. Schaap LA
    2. Pluijm SMF
    3. Deeg DJH
    4. Visser M

    (2006) Inflammatory Markers and Loss of Muscle Mass (Sarcopenia) and Strength

    The American Journal of Medicine 119:526.

    https://doi.org/10.1016/j.amjmed.2005.10.049

    • PubMed
    • Google Scholar
56. 1. Scialla JJ
    2. Wolf M

    (2014) Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease

    Nature Reviews. Nephrology 10:268–278.

    https://doi.org/10.1038/nrneph.2014.49

    • PubMed
    • Google Scholar
57. 1. Shiizaki K
    2. Tsubouchi A
    3. Miura Y
    4. Seo K
    5. Kuchimaru T
    6. Hayashi H
    7. Iwazu Y
    8. Miura M
    9. Battulga B
    10. Ohno N
    11. Hara T
    12. Kunishige R
    13. Masutani M
    14. Negishi K
    15. Kario K
    16. Kotani K
    17. Yamada T
    18. Nagata D
    19. Komuro I
    20. Itoh H
    21. Kurosu H
    22. Murata M
    23. Kuro-O M

    (2021) Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression

    The Journal of Clinical Investigation 131:145693.

    https://doi.org/10.1172/JCI145693

    • PubMed
    • Google Scholar
58. 1. Singh S
    2. Grabner A
    3. Yanucil C
    4. Schramm K
    5. Czaya B
    6. Krick S
    7. Czaja MJ
    8. Bartz R
    9. Abraham R
    10. Di Marco GS
    11. Brand M
    12. Wolf M
    13. Faul C

    (2016) Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease

    Kidney International 90:985–996.

    https://doi.org/10.1016/j.kint.2016.05.019

    • PubMed
    • Google Scholar
59. 1. Stenvinkel P
    2. Carrero JJ
    3. von Walden F
    4. Ikizler TA
    5. Nader GA

    (2016) Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies

    Nephrology, Dialysis, Transplantation 31:1070–1077.

    https://doi.org/10.1093/ndt/gfv122

    • PubMed
    • Google Scholar
60. 1. Sugihara K
    2. Masuda M
    3. Nakao M
    4. Abuduli M
    5. Imi Y
    6. Oda N
    7. Okahisa T
    8. Yamamoto H
    9. Takeda E
    10. Taketani Y

    (2017) Dietary phosphate exacerbates intestinal inflammation in experimental colitis

    Journal of Clinical Biochemistry and Nutrition 61:91–99.

    https://doi.org/10.3164/jcbn.16-117

    • PubMed
    • Google Scholar
61. 1. Takashi Y
    2. Kosako H
    3. Sawatsubashi S
    4. Kinoshita Y
    5. Ito N
    6. Tsoumpra MK
    7. Nangaku M
    8. Abe M
    9. Matsuhisa M
    10. Kato S
    11. Matsumoto T
    12. Fukumoto S

    (2019) Activation of unliganded FGF receptor by extracellular phosphate potentiates proteolytic protection of FGF23 by its O-glycosylation

    PNAS 116:201815166.

    https://doi.org/10.1073/pnas.1815166116

    • Google Scholar
62. 1. Taylor A
    2. Yanucil C
    3. Musgrove J
    4. Shi M
    5. Ide S
    6. Souma T
    7. Faul C
    8. Wolf M
    9. Grabner A

    (2019) FGFR4 does not contribute to progression of chronic kidney disease

    Scientific Reports 9:14023.

    https://doi.org/10.1038/s41598-019-50669-0

    • PubMed
    • Google Scholar
63. 1. Thomas L
    2. Xue J
    3. Murali SK
    4. Fenton RA
    5. Dominguez Rieg JA
    6. Rieg T

    (2019) Pharmacological Npt2a Inhibition Causes Phosphaturia and Reduces Plasma Phosphate in Mice with Normal and Reduced Kidney Function

    Journal of the American Society of Nephrology 30:2128–2139.

    https://doi.org/10.1681/ASN.2018121250

    • PubMed
    • Google Scholar
64. 1. Toussaint ND
    2. Pedagogos E
    3. Lioufas NM
    4. Elder GJ
    5. Pascoe EM
    6. Badve SV
    7. Valks A
    8. Block GA
    9. Boudville N
    10. Cameron JD
    11. Campbell KL
    12. Chen SSM
    13. Faull RJ
    14. Holt SG
    15. Jackson D
    16. Jardine MJ
    17. Johnson DW
    18. Kerr PG
    19. Lau KK
    20. Hooi LS
    21. Narayan O
    22. Perkovic V
    23. Polkinghorne KR
    24. Pollock CA
    25. Reidlinger D
    26. Robison L
    27. Smith ER
    28. Walker RJ
    29. Wang AYM
    30. Hawley CM
    31. Investigators ICT

    (2020) A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD

    Journal of the American Society of Nephrology 31:2653–2666.

    https://doi.org/10.1681/ASN.2020040411

    • PubMed
    • Google Scholar
65. 1. Tran L
    2. Batech M
    3. Rhee CM
    4. Streja E
    5. Kalantar-Zadeh K
    6. Jacobsen SJ
    7. Sim JJ

    (2016) Serum phosphorus and association with anemia among a large diverse population with and without chronic kidney disease

    Nephrology, Dialysis, Transplantation 31:636–645.

    https://doi.org/10.1093/ndt/gfv297

    • PubMed
    • Google Scholar
66. Preprint

    1. Turner ME
    2. Lansing AP
    3. Jeronimo PS
    4. Lee LH
    5. Svajger BA
    6. Zelt JG
    7. Forster CM
    8. Petkovich MP
    9. Holden RM
    10. Adams MA

    (2020) Vascular Calcification Has a Role in Acute Non-Renal Phosphate Clearance

    BioRxiv.

    https://doi.org/10.1101/2020.07.29.225532

    • Google Scholar
67. 1. Ugrica M
    2. Bettoni C
    3. Bourgeois S
    4. Daryadel A
    5. Pastor-Arroyo EM
    6. Gehring N
    7. Hernando N
    8. Wagner CA
    9. Rubio-Aliaga I

    (2021) A chronic high phosphate intake in mice is detrimental for bone health without major renal alterations

    Nephrology, Dialysis, Transplantation 36:1183–1191.

    https://doi.org/10.1093/ndt/gfab015

    • PubMed
    • Google Scholar
68. 1. Verga Falzacappa MV
    2. Vujic Spasic M
    3. Kessler R
    4. Stolte J
    5. Hentze MW
    6. Muckenthaler MU

    (2007) STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation

    Blood 109:353–358.

    https://doi.org/10.1182/blood-2006-07-033969

    • PubMed
    • Google Scholar
69. 1. Verzola D
    2. Bonanni A
    3. Sofia A
    4. Montecucco F
    5. D’Amato E
    6. Cademartori V
    7. Parodi EL
    8. Viazzi F
    9. Venturelli C
    10. Brunori G
    11. Garibotto G

    (2017) Toll‐like receptor 4 signalling mediates inflammation in skeletal muscle of patients with chronic kidney disease

    Journal of Cachexia, Sarcopenia and Muscle 8:131–144.

    https://doi.org/10.1002/jcsm.12129

    • PubMed
    • Google Scholar
70. 1. Verzola D
    2. Barisione C
    3. Picciotto D
    4. Garibotto G
    5. Koppe L

    (2019) Emerging role of myostatin and its inhibition in the setting of chronic kidney disease

    Kidney International 95:506–517.

    https://doi.org/10.1016/j.kint.2018.10.010

    • PubMed
    • Google Scholar
71. 1. Villa-Bellosta R
    2. Bogaert YE
    3. Levi M
    4. Sorribas V

    (2007) Characterization of Phosphate Transport in Rat Vascular Smooth Muscle Cells

    Arteriosclerosis, Thrombosis, and Vascular Biology 27:1030–1036.

    https://doi.org/10.1161/ATVBAHA.106.132266

    • PubMed
    • Google Scholar
72. 1. Villa-Bellosta R
    2. Sorribas V

    (2009) Phosphonoformic Acid Prevents Vascular Smooth Muscle Cell Calcification by Inhibiting Calcium-Phosphate Deposition

    Arteriosclerosis, Thrombosis, and Vascular Biology 29:761–766.

    https://doi.org/10.1161/ATVBAHA.108.183384

    • PubMed
    • Google Scholar
73. 1. Voelkl J
    2. Tuffaha R
    3. Luong TTD
    4. Zickler D
    5. Masyout J
    6. Feger M
    7. Verheyen N
    8. Blaschke F
    9. Kuro-O M
    10. Tomaschitz A
    11. Pilz S
    12. Pasch A
    13. Eckardt K-U
    14. Scherberich JE
    15. Lang F
    16. Pieske B
    17. Alesutan I

    (2018) Zinc Inhibits Phosphate-Induced Vascular Calcification through TNFAIP3-Mediated Suppression of NF-κB

    Journal of the American Society of Nephrology 29:1636–1648.

    https://doi.org/10.1681/ASN.2017050492

    • PubMed
    • Google Scholar
74. 1. Wang XH
    2. Mitch WE

    (2014) Mechanisms of muscle wasting in chronic kidney disease

    Nature Reviews. Nephrology 10:504–516.

    https://doi.org/10.1038/nrneph.2014.112

    • PubMed
    • Google Scholar
75. 1. Weinstein M
    2. Xu X
    3. Ohyama K
    4. Deng CX

    (1998) FGFR-3 and FGFR-4 function cooperatively to direct alveogenesis in the murine lung

    Development (Cambridge, England) 125:3615–3623.

    https://doi.org/10.1242/dev.125.18.3615

    • PubMed
    • Google Scholar
76. 1. White KE
    2. Carn G
    3. Lorenz-Depiereux B
    4. Benet-Pages A
    5. Strom TM
    6. Econs MJ

    (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23

    Kidney International 60:2079–2086.

    https://doi.org/10.1046/j.1523-1755.2001.00064.x

    • PubMed
    • Google Scholar
77. 1. Wojcicki JM

    (2013) Hyperphosphatemia is associated with anemia in adults without chronic kidney disease: results from the National Health and Nutrition Examination Survey (NHANES): 2005–2010

    BMC Nephrology 14:178.

    https://doi.org/10.1186/1471-2369-14-178

    • PubMed
    • Google Scholar
78. 1. Wolf M

    (2012) Update on fibroblast growth factor 23 in chronic kidney disease

    Kidney International 82:737–747.

    https://doi.org/10.1038/ki.2012.176

    • PubMed
    • Google Scholar
79. 1. Xiao Z
    2. King G
    3. Mancarella S
    4. Munkhsaikhan U
    5. Cao L
    6. Cai C
    7. Quarles LD

    (2019) FGF23 expression is stimulated in transgenic α-Klotho longevity mouse model

    JCI Insight 4:132820.

    https://doi.org/10.1172/jci.insight.132820

    • PubMed
    • Google Scholar
80. 1. Yamada S
    2. Tokumoto M
    3. Tatsumoto N
    4. Taniguchi M
    5. Noguchi H
    6. Nakano T
    7. Masutani K
    8. Ooboshi H
    9. Tsuruya K
    10. Kitazono T

    (2014) Phosphate overload directly induces systemic inflammation and malnutrition as well as vascular calcification in uremia

    American Journal of Physiology. Renal Physiology 306:1418–1428.

    https://doi.org/10.1152/ajprenal.00633.2013

    • PubMed
    • Google Scholar
81. 1. Zelt JG
    2. Svajger BA
    3. Quinn K
    4. Turner ME
    5. Laverty KJ
    6. Shum B
    7. Holden RM
    8. Adams MA

    (2019) Acute Tissue Mineral Deposition in Response to a Phosphate Pulse in Experimental CKD

    Journal of Bone and Mineral Research 34:270–281.

    https://doi.org/10.1002/jbmr.3572

    • PubMed
    • Google Scholar
82. 1. Zhang L
    2. Rajan V
    3. Lin E
    4. Hu Z
    5. Han HQ
    6. Zhou X
    7. Song Y
    8. Min H
    9. Wang X
    10. Du J
    11. Mitch WE

    (2011) Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease

    FASEB Journal 25:1653–1663.

    https://doi.org/10.1096/fj.10-176917

    • PubMed
    • Google Scholar
83. 1. Zhang L
    2. Pan J
    3. Dong Y
    4. Tweardy DJ
    5. Dong Y
    6. Garibotto G
    7. Mitch WE

    (2013) Stat3 Activation Links a C/EBPδ to Myostatin Pathway to Stimulate Loss of Muscle Mass

    Cell Metabolism 18:368–379.

    https://doi.org/10.1016/j.cmet.2013.07.012

    • PubMed
    • Google Scholar
84. 1. Zhao MM
    2. Xu MJ
    3. Cai Y
    4. Zhao G
    5. Guan Y
    6. Kong W
    7. Tang C
    8. Wang X

    (2011) Mitochondrial reactive oxygen species promote p65 nuclear translocation mediating high-phosphate-induced vascular calcification in vitro and in vivo

    Kidney International 79:1071–1079.

    https://doi.org/10.1038/ki.2011.18

    • PubMed
    • Google Scholar
85. 1. Zhou Z
    2. Xu MJ
    3. Gao B

    (2016) Hepatocytes: a key cell type for innate immunity

    Cellular & Molecular Immunology 13:301–315.

    https://doi.org/10.1038/cmi.2015.97

    • PubMed
    • Google Scholar

Author details

1. Brian Czaya

   1. Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States
   2. Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, United States

   Contribution

   Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-7888-2432

2. Kylie Heitman

   Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-5345-2727

3. Isaac Campos

   Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

4. Christopher Yanucil

   Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

5. Dominik Kentrup

   Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

   Contribution

   Formal analysis, Methodology

   Competing interests

   No competing interests declared

6. David Westbrook

   Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

   Contribution

   Project administration

   Competing interests

   No competing interests declared

7. Orlando Gutierrez

   Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

   Contribution

   Conceptualization

   Competing interests

   has received honoraria and grant support from Akebia and Amgen, grant support from GSK, honoraria from Ardelyx, Reata, and AstraZeneca, and serves on the Data Monitoring Committee for QED

8. Jodie L Babitt

   Division of Nephrology, Program in Membrane Biology, Massachusetts General Hospital, Harvard Medical School, Boston, United States

   Contribution

   Conceptualization, Methodology

   Competing interests

   has ownership interest in Ferrumax Pharmaceuticals and has been a consultant for Incyte Corporation, and Alnylam Pharmaceuticals

9. Grace Jung

   Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, United States

   Contribution

   Investigation, Methodology

   Competing interests

   No competing interests declared

10. Isidro B Salusky

    Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States

    Contribution

    Conceptualization, Investigation

    Competing interests

    No competing interests declared

11. Mark Hanudel

    Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, United States

    Contribution

    Conceptualization, Investigation, Methodology

    Competing interests

    No competing interests declared

12. Christian Faul

    Division of Nephrology and Hypertension, Department of Medicine, The University of Alabama at Birmingham, Birmingham, United States

    Contribution

    Conceptualization, Funding acquisition, Investigation, Project administration, Resources, Supervision, Writing – original draft

    For correspondence

    cfaul@uabmc.edu

    Competing interests

    has served as a consultant for Bayer and Calico Labs, and he is the founder and currently the CSO of a startup biotech company (Alpha Young LLC)

    "This ORCID iD identifies the author of this article:" 0000-0002-7512-0977

• 2,101

  views

• 290

  downloads

• 23

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.